Search results for: 'biological solutions'

This study focuses on emerging pharmacological and non-pharmacological strategies in the treatment of obesity, as well as evolving new paradigms for the future. It describes the contribution of incretin-based therapies, particularly GLP-1 receptor agonists and their multi-agonist counterparts, which provide robust effects on weight loss and metabol...

09 May 2025  |  Global  |  Technology Research

Emerging Anti-aging strategies

Evolving Anti-aging Strategies Are Driving Transformational Growth in Innovation, Market Players, and Emerging Opportunities

Infographics

×

This report delves into the rapidly evolving anti-aging industry, highlighting the breakthrough innovations in cellular and genomic rejuvenation as well as AI/ML-driven anti-aging strategies. It explores the industry ecosystem, covering key players, emerging players, and academic researchers transforming the field. The analysis includes major techn...

Over the last 3-5 years, growing cost pressure on healthcare and pharmaceutical companies and a significant shift towards outcome based healthcare approach have resulted in companies increasingly adopting real world data and evidence solutions to optimize their operation and cost using analytics. Earlier, applications of RWE were largely limited to...

The report explores the transformation of obesity care from generalized BMI-based treatment to AI-enabled precision metabolic management. The study highlights how obesity is increasingly recognized as a heterogeneous, multi-pathway disease influenced by genetic, neurobehavioral, metabolic, and environmental factors, requiring personalized therapeut...

The US and European mammalian contract development and manufacturing organization (CDMO) market is entering a new phase of strategic evolution, driven by accelerating biologics outsourcing, increasing molecule complexity, and growing demand for resilient, end-to-end manufacturing partnerships. As monoclonal antibodies, bispecific antibodies, Fc-fus...

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) delivers strategic insights into breakthrough innovations shaping the future of healthcare, life sciences, and precision medicine. It highlights AI-driven platforms, advanced biologics, and digital health solutions that address critical challenges in accessibili...

The biopharma industry has been evolving over the past few decades. This study analyses the top ten trends that will impact the future of the biopharma industry through 2040.The future of biopharma will be driven by innovation in AI and ML, particularly generative AI, and by advancements in translational medicine and synthetic biology. Future clini...

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) delivers provides strategic insights into breakthrough innovations shaping the future of healthcare, life sciences, and precision therapeutics. It highlights advances in AI-enabled diagnostics, metabolic reprogramming, small molecules, deep proteomics, RNA disco...

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) provides strategic insights into frontier innovations redefining therapeutic development, precision diagnostics, and immune modulating interventions. It showcases breakthroughs across engineered phage therapeutics, intracellular peptide platforms, advanced gene ...